For ophthalmologists who have decided to add an optical dispensary to their offices, the process of designing and equipping the space can be a daunting experience. Far more than just attaching frame display racks to the walls, the optical dispensary should be coordinated and blended with the decor and design of the rest of the office. It should also be designed for maximum efficiency and represent the doctors' aesthetic tastes.
Read More
Releasable scleral-flap suture effective for trabeculectomy
July 15th 2003Cincinnati, OH-Releasable scleral-flap sutures reduce the incidence of a shallow and flat anterior chamber after trabeculectomy, without compromising long-term control of IOP, according to glaucoma specialist John S. Cohen, MD.
Read More
Disposable intraocular tool advances vitreoretinal surgery
July 1st 2003The introduction of the Grieshaber Revolution DSP (Alcon) line of disposable intraocular instruments represents a true innovation in the evolution of vitreoretinal surgery, according to retinal specialists Peter Kaiser, MD, and Allen C. Ho, MD.
Read More
Be proactive to avoid lawsuits from noncompliant patients
June 15th 2003San Francisco-Patients who repeatedly miss appointments or do not follow prescribed treatment plans can be walking litigation time bombs, according to attorney Paul Weber, JD, a risk manager at the Ophthalmic Mutual Insurance Co.
Read More
New software reduces OCT measurement variability
June 1st 2003San Francisco-The newest version (A2) of the Carl Zeiss Meditec software algorithm for quantification of retinal nerve fiber layer (RNFL) thickness using the third-generation optical coherence tomography (OCT 3) showed no improvement in glaucoma discriminating power compared with its predecessor software (A1), but it did reduce the variability of RNFL thickness measurements, according to a Tufts University glaucoma specialist.
Read More
Better glaucoma detection, treatment needed for future
June 1st 2003San Francisco-Nearly 100,000 people in the United States are blind from glaucoma, and this number will rise enormously as the population ages over the next 20 years unless better detection and treatment methods are developed, said Nathan G. Congdon, MD, MPH.
Read More
Corticosteroid shown to be safe for long-term SAC control
May 1st 2003Tampa, FL-Loteprednol etabonate ophthalmic suspension 0.2% (Alrex, Bausch & Lomb Pharmaceuticals and Pharmos Corp.), the first corticosteroid specifically designed for signs and symptoms of seasonal allergic conjunctivitis (SAC), is safe for long-term use, according to a recent multicenter study.
Read More